Was Anatol Kreitzer’s MPLT share sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025 . Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from discretionary market-timed decisions.

How many MPLT share sale transactions did the Form 4 report for April 27, 2026?

The Form 4 reports three non-derivative transactions in Voting Common Stock on April 27, 2026. Together they total 45,422 shares sold in open-market trades at different weighted average prices, with each line item listing a separate price and share amount.

MapLight Therapeutics (NASDAQ: MPLT) CDO sells 45,422 shares under 10b5-1 plan

Q: What insider transaction did MPLT Chief Discovery Officer Anatol Kreitzer report?

Anatol Kreitzer reported selling 45,422 shares of MapLight Therapeutics Voting Common Stock in open-market transactions on April 27, 2026 . The filing shows three separate sales at different weighted average prices under a pre-arranged Rule 10b5-1 trading plan .

Q: At what prices did Anatol Kreitzer sell MPLT shares on April 27, 2026?

Kreitzer’s reported weighted average sale prices were $28.96 , $29.63 , and $30.50 per share. Each price reflects multiple trades within a specific intraday range, as detailed in the Form 4 footnotes describing the applicable price bands for the transactions.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 45,422 shares of Voting Common Stock in open-market transactions. The sales occurred on April 27, 2026 at weighted average prices of $28.96, $29.63, and $30.50 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Kreitzer directly held 211,190 shares of MapLight Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 45,422 shares ($1,347,066)

Net Sell 3 txns

Insider Kreitzer Anatol

Role Chief Discovery Officer

Sold 45,422 shs ($1.35M)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	8,346	$28.96	$242K
Sale	Voting Common Stock	29,255	$29.63	$867K
Sale	Voting Common Stock	7,821	$30.50	$239K

Holdings After Transaction: Voting Common Stock — 248,266 shares (Direct, null)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.27 to $30.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 45,422 shares Post-sale holdings: 211,190 shares Sale tranche 1: 7,821 shares at $30.50 +3 more

6 metrics

Total shares sold 45,422 shares Aggregate open-market sales on April 27, 2026

Post-sale holdings 211,190 shares Direct Voting Common Stock after transactions

Sale tranche 1 7,821 shares at $30.50 Voting Common Stock, open-market sale

Sale tranche 2 29,255 shares at $29.63 Voting Common Stock, open-market sale

Sale tranche 3 8,346 shares at $28.96 Voting Common Stock, open-market sale

Transaction date April 27, 2026 Date of reported open-market sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Voting Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Voting Common Stock financial

"security_title: Voting Common Stock"

Form 4 Insider Transactions: What Each Field Means →

04/29/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kreitzer Anatol

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Discovery Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	04/27/2026		S⁽¹⁾		8,346	D	$28.96⁽²⁾	248,266	D
Voting Common Stock	04/27/2026		S⁽¹⁾		29,255	D	$29.63⁽³⁾	219,011	D
Voting Common Stock	04/27/2026		S⁽¹⁾		7,821	D	$30.5⁽⁴⁾	211,190	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.27 to $30.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MPLT Chief Discovery Officer Anatol Kreitzer report?

Anatol Kreitzer reported selling 45,422 shares of MapLight Therapeutics Voting Common Stock in open-market transactions on April 27, 2026. The filing shows three separate sales at different weighted average prices under a pre-arranged Rule 10b5-1 trading plan.

At what prices did Anatol Kreitzer sell MPLT shares on April 27, 2026?

Kreitzer’s reported weighted average sale prices were $28.96, $29.63, and $30.50 per share. Each price reflects multiple trades within a specific intraday range, as detailed in the Form 4 footnotes describing the applicable price bands for the transactions.

How many MapLight Therapeutics (MPLT) shares does Anatol Kreitzer hold after the sale?

Following the reported open-market sales, Kreitzer directly holds 211,190 shares of MapLight Therapeutics Voting Common Stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects his remaining direct equity stake after the April 27, 2026 trades.

What price ranges are associated with the weighted average MPLT sale prices reported?

Footnotes explain that trades underlying the weighted averages occurred in ranges: $28.27–$29.26, $29.27–$30.26, and $30.27–$30.64. Kreitzer undertakes to provide detailed trade-by-trade pricing information upon request to the issuer, security holders, or SEC staff.